Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4547 in Urothelial Carcinoma with FGFR2/3 Alterations
NCT05086666Phase 2Unknown
- Sponsor
- Abbisko Therapeutics
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fexagratinib in urothelial carcinoma (UC), sponsored by Abbisko Therapeutics. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events and Serious Adverse Events at 6 months and 1 more. Status: unknown.
02
Drugs
fexagratinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05086666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05086666.